-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Ch4Y7OY3Ra9o3MQPnQwKl7Am5JLoxXzU9/3wCdgidN1SHimASbDw6ZZuwreL8WVF zPemOifPkNnIYiW3PXMoGA== /in/edgar/work/20000605/0000062391-00-000002/0000062391-00-000002.txt : 20000919 0000062391-00-000002.hdr.sgml : 20000919 ACCESSION NUMBER: 0000062391-00-000002 CONFORMED SUBMISSION TYPE: SC 13G/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20000605 GROUP MEMBERS: HMR PHARMA, INC. & AVENTIS PHARMACEUTICALS INC. GROUP MEMBERS: HOECHST MARION ROUSSEL INC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ARIAD PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000884731 STANDARD INDUSTRIAL CLASSIFICATION: [2836 ] IRS NUMBER: 223106987 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A SEC ACT: SEC FILE NUMBER: 005-48751 FILM NUMBER: 649160 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE ST CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 6174940400 MAIL ADDRESS: STREET 2: 26 LANDSDOWNE CITY: CAMBRIDGE STATE: MA ZIP: 02139 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: HOECHST MARION ROUSSEL INC CENTRAL INDEX KEY: 0000062391 STANDARD INDUSTRIAL CLASSIFICATION: [2834 ] IRS NUMBER: 440565557 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G/A BUSINESS ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 BUSINESS PHONE: 8169665000 MAIL ADDRESS: STREET 1: 10236 MARION PARK DRIVE STREET 2: P O BOX 9627 CITY: KANSAS CITY STATE: MO ZIP: 64134-0627 FORMER COMPANY: FORMER CONFORMED NAME: MARION MERRELL DOW INC DATE OF NAME CHANGE: 19920703 FORMER COMPANY: FORMER CONFORMED NAME: MARION LABORATORIES INC DATE OF NAME CHANGE: 19891218 SC 13G/A 1 0001.txt AMEND #3 TO ARIAD PHARMACEUTICALS SCHEDULE 13G =========================================================================== SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 3 Under the Securities Exchange Act of 1934 ARIAD PHARMACEUTICALS, INC. ---------------------------- (Name of Issuer) COMMON STOCK, $.001 PAR VALUE - --------------------------------------------------------------------------- (Title of Class of Securities) 04033A 10 0 ----------------- (CUSIP Number) December 31, 1999 ------------------------------------------------------- (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ x ] Rule 13d-1(c) [ ] Rule 13d-1(d) =========================================================================== Page 1 of 8 Exhibit Index is located at page 7 2 CUSIP No. 04033A 10 0 - --------------------------------------------------------------------------- 1) Name of Reporting Person and its Aventis Pharmaceuticals Inc. I.R.S. Identification Number 44-0565557 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 0 Number of ____________________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 0 Person With ____________________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 0 by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented 0% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- 3 CUSIP No. 04033A 10 0 13G - --------------------------------------------------------------------------- 1) Name of Reporting Person and its HMR Pharma, Inc. I.R.S. Identification Number 43-1769328 - --------------------------------------------------------------------------- 2) Check the Appropriate Box if (a)[ ] a Member of a Group (b)[ x ] - --------------------------------------------------------------------------- 3) SEC Use Only - --------------------------------------------------------------------------- 4) Citizenship or Place of Organization Delaware - --------------------------------------------------------------------------- 5) Sole Voting Power 0 Number of ____________________________________________________________ Shares Beneficially 6) Shared Voting Power 0 Owned by ____________________________________________________________ Each Reporting 7) Sole Dispositive Power 0 Person With ____________________________________________________________ 8) Shared Dispositive Power 0 - --------------------------------------------------------------------------- 9) Aggregate Amount Beneficially Owned 0 by Each Reporting Person - --------------------------------------------------------------------------- 10) Check Box If the Aggregate Amount [ ] in Row (9) Excludes Certain Shares - --------------------------------------------------------------------------- 11) Percent of Class Represented 0% by Amount in Row (9) - --------------------------------------------------------------------------- 12) Type of Reporting Person CO - --------------------------------------------------------------------------- 4 CUSIP No. 04033A 10 0 13G This Amendment No. 3 to the Statement on Schedule 13G of Aventis Pharmaceuticals Inc., a Delaware corporation, and HMR Pharma, Inc., a Delaware corporation, is filed solely to reflect the disposition of all of the shares of Ariad Pharmaceuticals, Inc. The following items of the Statement on Schedule 13G are hereby amended to read as follows: ITEM 4. OWNERSHIP - ------- --------- (a): AMOUNT BENEFICIALLY OWNED: As Of 12/31/99 0 Shares of Series B Convertible Preferred Stock. On 12/31/99 3,004,436 Shares of Series B Convertible Preferred Stock were surrendered to Issuer. (b): PERCENT OF CLASS: 0% (c): NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS: (i) Sole power to vote or to direct the vote: 0 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the 0 disposition of: (iv) Shared power to dispose or to direct the 0 disposition of: 5 CUSIP No. 04033A 10 0 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. June 5, 2000 --------------------------------- (Date) HMR PHARMA, INC. /s/ Joan A. Hanlon --------------------------------- (Signature) Joan A. Hanlon Vice President and Treasurer --------------------------------- (Name/Title) 6 CUSIP No. 04033A 10 0 13G SIGNATURE ---------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. June 5, 2000 --------------------------------- (Date) Aventis Pharmaceuticals INC. /s/ Rebecca R. Tilden --------------------------------- (Signature) Rebecca R. Tilden Vice President and Secretary --------------------------------- (Name/Title) 7 CUSIP No. 04033A 10 0 13G EXHIBIT INDEX Exhibit No. Description Page No. - ----------- ------------ --------- 99.A Agreement to File Jointly dated June 8 5, 2000, by and between Aventis Pharmaceuticals Inc. and HMR Pharma, Inc. 8 CUSIP No. 04033A 10 0 13G EXHIBIT 99.A AGREEMENT TO FILE JOINTLY We, the undersigned, hereby express our agreement that the attached Schedule 13G is filed on behalf of each of us. AVENTIS PHARMACEUTICALS INC. Date: June 5, 2000 By: /s/ Rebecca R. Tilden -------------------------- Rebecca R. Tilden Vice President and Secretary HMR PHARMA, INC. Date: June 5, 2000 By: /s/ Joan A. Hanlon -------------------------- Joan A. Hanlon Vice President and Treasurer -----END PRIVACY-ENHANCED MESSAGE-----